Skip to main content

Gold Nanoparticles Bearing Functional Anti-Cancer Drug and Anti-Angiogenic Agent: A "2 in 1" System with Potential Application in Cancer Therapeutics

Buy Article:

$113.00 plus tax (Refund Policy)


Angiogenesis, the formation of new blood vessels from a pre-existing vessel, is a necessary step for tumor growth and metastasis. Combination therapy using anti-angiogenic molecule and cytotoxic agents is a promising approach in anti-cancer therapy. However, the underlying problem in the use of anti-cancer drug is that they have short half-lives with extensive systemic toxicity. However, when delivered in a gold-conjugated form, these molecules might have increased retention in the body with reduced systemic toxicity. In this study a nano-composite system consisting of a nanogold core bearing an anti-angiogenic molecule, VEGF antibody-2C3 (AbVF), along with an anti-cancer drug, gemcitabine has been reported. The physico-chemical characterization of these nanocomposites was performed using UV-Visible (UV-Vis) spectroscopy and transmission electron microscopy (TEM). The functional activity of the individual components in the nanocomposites was tested on HUVEC (human umbilical vein endothelial cells) and 786-O cells and showed retention of functional activity of both VEGF antibody and gemcitabine. This provides a unique "2 in 1" system where 2 components with different functions have been attached onto a single gold core, yet the functional activity of the individual components are retained. These nano-composites might find potential applications in the treatment of cancer.


Document Type: Short Communication


Publication date: 2005-06-01

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free ContentFree content
  • Partial Free ContentPartial Free content
  • New ContentNew content
  • Open Access ContentOpen access content
  • Partial Open Access ContentPartial Open access content
  • Subscribed ContentSubscribed content
  • Partial Subscribed ContentPartial Subscribed content
  • Free Trial ContentFree trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more